The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Metabolic Disorder Therapeutics Market Research Report 2025
Synopsis
The global Metabolic Disorder Therapeutics market was valued at US$ 46680 million in 2023 and is anticipated to reach US$ 64560 million by 2030, witnessing a CAGR of 4.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Metabolic Disorder Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metabolic Disorder Therapeutics.
Report Scope
The Metabolic Disorder Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Metabolic Disorder Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Metabolic Disorder Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novo Nordisk A/S
Sanofi S.A.
Boehringer Ingelheim GmbH
Eli Lilly and Company
Merck KgaA
Amgen, Inc.
AstraZeneca PLC
Actelion Pharmaceuticals Ltd.
Shire PLC
AbbVie, Inc.
Biocon Ltd.
BioMarin Pharmaceutical, Inc.
Bristol-Myers Squibb Company
Cipla, Inc.
CymaBay Therapeutics, Inc.
Segment by Type
Lysosomal Storage Diseases
Diabetes
Obesity
Inherited Metabolic Disorders
Hypercholesterolemia
Segment by Application
Oral
Parenteral
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Metabolic Disorder Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Metabolic Disorder Therapeutics market was valued at US$ 46680 million in 2023 and is anticipated to reach US$ 64560 million by 2030, witnessing a CAGR of 4.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Metabolic Disorder Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metabolic Disorder Therapeutics.
Report Scope
The Metabolic Disorder Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Metabolic Disorder Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Metabolic Disorder Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novo Nordisk A/S
Sanofi S.A.
Boehringer Ingelheim GmbH
Eli Lilly and Company
Merck KgaA
Amgen, Inc.
AstraZeneca PLC
Actelion Pharmaceuticals Ltd.
Shire PLC
AbbVie, Inc.
Biocon Ltd.
BioMarin Pharmaceutical, Inc.
Bristol-Myers Squibb Company
Cipla, Inc.
CymaBay Therapeutics, Inc.
Segment by Type
Lysosomal Storage Diseases
Diabetes
Obesity
Inherited Metabolic Disorders
Hypercholesterolemia
Segment by Application
Oral
Parenteral
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Metabolic Disorder Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Lysosomal Storage Diseases
1.2.3 Diabetes
1.2.4 Obesity
1.2.5 Inherited Metabolic Disorders
1.2.6 Hypercholesterolemia
1.3 Market by Application
1.3.1 Global Metabolic Disorder Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Oral
1.3.3 Parenteral
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Metabolic Disorder Therapeutics Market Perspective (2019-2030)
2.2 Metabolic Disorder Therapeutics Growth Trends by Region
2.2.1 Global Metabolic Disorder Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Metabolic Disorder Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Metabolic Disorder Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Metabolic Disorder Therapeutics Market Dynamics
2.3.1 Metabolic Disorder Therapeutics Industry Trends
2.3.2 Metabolic Disorder Therapeutics Market Drivers
2.3.3 Metabolic Disorder Therapeutics Market Challenges
2.3.4 Metabolic Disorder Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Metabolic Disorder Therapeutics Players by Revenue
3.1.1 Global Top Metabolic Disorder Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Metabolic Disorder Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Metabolic Disorder Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Metabolic Disorder Therapeutics Revenue
3.4 Global Metabolic Disorder Therapeutics Market Concentration Ratio
3.4.1 Global Metabolic Disorder Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metabolic Disorder Therapeutics Revenue in 2023
3.5 Metabolic Disorder Therapeutics Key Players Head office and Area Served
3.6 Key Players Metabolic Disorder Therapeutics Product Solution and Service
3.7 Date of Enter into Metabolic Disorder Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Metabolic Disorder Therapeutics Breakdown Data by Type
4.1 Global Metabolic Disorder Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Type (2025-2030)
5 Metabolic Disorder Therapeutics Breakdown Data by Application
5.1 Global Metabolic Disorder Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Metabolic Disorder Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Metabolic Disorder Therapeutics Market Size (2019-2030)
6.2 North America Metabolic Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Metabolic Disorder Therapeutics Market Size by Country (2019-2024)
6.4 North America Metabolic Disorder Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Metabolic Disorder Therapeutics Market Size (2019-2030)
7.2 Europe Metabolic Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Metabolic Disorder Therapeutics Market Size by Country (2019-2024)
7.4 Europe Metabolic Disorder Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Metabolic Disorder Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Metabolic Disorder Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Metabolic Disorder Therapeutics Market Size (2019-2030)
9.2 Latin America Metabolic Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Metabolic Disorder Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Metabolic Disorder Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Metabolic Disorder Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Metabolic Disorder Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novo Nordisk A/S
11.1.1 Novo Nordisk A/S Company Detail
11.1.2 Novo Nordisk A/S Business Overview
11.1.3 Novo Nordisk A/S Metabolic Disorder Therapeutics Introduction
11.1.4 Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2019-2024)
11.1.5 Novo Nordisk A/S Recent Development
11.2 Sanofi S.A.
11.2.1 Sanofi S.A. Company Detail
11.2.2 Sanofi S.A. Business Overview
11.2.3 Sanofi S.A. Metabolic Disorder Therapeutics Introduction
11.2.4 Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)
11.2.5 Sanofi S.A. Recent Development
11.3 Boehringer Ingelheim GmbH
11.3.1 Boehringer Ingelheim GmbH Company Detail
11.3.2 Boehringer Ingelheim GmbH Business Overview
11.3.3 Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Introduction
11.3.4 Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2019-2024)
11.3.5 Boehringer Ingelheim GmbH Recent Development
11.4 Eli Lilly and Company
11.4.1 Eli Lilly and Company Company Detail
11.4.2 Eli Lilly and Company Business Overview
11.4.3 Eli Lilly and Company Metabolic Disorder Therapeutics Introduction
11.4.4 Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2019-2024)
11.4.5 Eli Lilly and Company Recent Development
11.5 Merck KgaA
11.5.1 Merck KgaA Company Detail
11.5.2 Merck KgaA Business Overview
11.5.3 Merck KgaA Metabolic Disorder Therapeutics Introduction
11.5.4 Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2019-2024)
11.5.5 Merck KgaA Recent Development
11.6 Amgen, Inc.
11.6.1 Amgen, Inc. Company Detail
11.6.2 Amgen, Inc. Business Overview
11.6.3 Amgen, Inc. Metabolic Disorder Therapeutics Introduction
11.6.4 Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)
11.6.5 Amgen, Inc. Recent Development
11.7 AstraZeneca PLC
11.7.1 AstraZeneca PLC Company Detail
11.7.2 AstraZeneca PLC Business Overview
11.7.3 AstraZeneca PLC Metabolic Disorder Therapeutics Introduction
11.7.4 AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2019-2024)
11.7.5 AstraZeneca PLC Recent Development
11.8 Actelion Pharmaceuticals Ltd.
11.8.1 Actelion Pharmaceuticals Ltd. Company Detail
11.8.2 Actelion Pharmaceuticals Ltd. Business Overview
11.8.3 Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Introduction
11.8.4 Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)
11.8.5 Actelion Pharmaceuticals Ltd. Recent Development
11.9 Shire PLC
11.9.1 Shire PLC Company Detail
11.9.2 Shire PLC Business Overview
11.9.3 Shire PLC Metabolic Disorder Therapeutics Introduction
11.9.4 Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2019-2024)
11.9.5 Shire PLC Recent Development
11.10 AbbVie, Inc.
11.10.1 AbbVie, Inc. Company Detail
11.10.2 AbbVie, Inc. Business Overview
11.10.3 AbbVie, Inc. Metabolic Disorder Therapeutics Introduction
11.10.4 AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)
11.10.5 AbbVie, Inc. Recent Development
11.11 Biocon Ltd.
11.11.1 Biocon Ltd. Company Detail
11.11.2 Biocon Ltd. Business Overview
11.11.3 Biocon Ltd. Metabolic Disorder Therapeutics Introduction
11.11.4 Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)
11.11.5 Biocon Ltd. Recent Development
11.12 BioMarin Pharmaceutical, Inc.
11.12.1 BioMarin Pharmaceutical, Inc. Company Detail
11.12.2 BioMarin Pharmaceutical, Inc. Business Overview
11.12.3 BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Introduction
11.12.4 BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)
11.12.5 BioMarin Pharmaceutical, Inc. Recent Development
11.13 Bristol-Myers Squibb Company
11.13.1 Bristol-Myers Squibb Company Company Detail
11.13.2 Bristol-Myers Squibb Company Business Overview
11.13.3 Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Introduction
11.13.4 Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2019-2024)
11.13.5 Bristol-Myers Squibb Company Recent Development
11.14 Cipla, Inc.
11.14.1 Cipla, Inc. Company Detail
11.14.2 Cipla, Inc. Business Overview
11.14.3 Cipla, Inc. Metabolic Disorder Therapeutics Introduction
11.14.4 Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)
11.14.5 Cipla, Inc. Recent Development
11.15 CymaBay Therapeutics, Inc.
11.15.1 CymaBay Therapeutics, Inc. Company Detail
11.15.2 CymaBay Therapeutics, Inc. Business Overview
11.15.3 CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Introduction
11.15.4 CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024)
11.15.5 CymaBay Therapeutics, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Metabolic Disorder Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Lysosomal Storage Diseases
Table 3. Key Players of Diabetes
Table 4. Key Players of Obesity
Table 5. Key Players of Inherited Metabolic Disorders
Table 6. Key Players of Hypercholesterolemia
Table 7. Global Metabolic Disorder Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Metabolic Disorder Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Metabolic Disorder Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 10. Global Metabolic Disorder Therapeutics Market Share by Region (2019-2024)
Table 11. Global Metabolic Disorder Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 12. Global Metabolic Disorder Therapeutics Market Share by Region (2025-2030)
Table 13. Metabolic Disorder Therapeutics Market Trends
Table 14. Metabolic Disorder Therapeutics Market Drivers
Table 15. Metabolic Disorder Therapeutics Market Challenges
Table 16. Metabolic Disorder Therapeutics Market Restraints
Table 17. Global Metabolic Disorder Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 18. Global Metabolic Disorder Therapeutics Market Share by Players (2019-2024)
Table 19. Global Top Metabolic Disorder Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disorder Therapeutics as of 2023)
Table 20. Ranking of Global Top Metabolic Disorder Therapeutics Companies by Revenue (US$ Million) in 2023
Table 21. Global 5 Largest Players Market Share by Metabolic Disorder Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Metabolic Disorder Therapeutics Product Solution and Service
Table 24. Date of Enter into Metabolic Disorder Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Metabolic Disorder Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 27. Global Metabolic Disorder Therapeutics Revenue Market Share by Type (2019-2024)
Table 28. Global Metabolic Disorder Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 29. Global Metabolic Disorder Therapeutics Revenue Market Share by Type (2025-2030)
Table 30. Global Metabolic Disorder Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 31. Global Metabolic Disorder Therapeutics Revenue Market Share by Application (2019-2024)
Table 32. Global Metabolic Disorder Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 33. Global Metabolic Disorder Therapeutics Revenue Market Share by Application (2025-2030)
Table 34. North America Metabolic Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. North America Metabolic Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 36. North America Metabolic Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 37. Europe Metabolic Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 38. Europe Metabolic Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 39. Europe Metabolic Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 40. Asia-Pacific Metabolic Disorder Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 41. Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 42. Asia-Pacific Metabolic Disorder Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 43. Latin America Metabolic Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Latin America Metabolic Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 45. Latin America Metabolic Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 46. Middle East & Africa Metabolic Disorder Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 47. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 48. Middle East & Africa Metabolic Disorder Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 49. Novo Nordisk A/S Company Detail
Table 50. Novo Nordisk A/S Business Overview
Table 51. Novo Nordisk A/S Metabolic Disorder Therapeutics Product
Table 52. Novo Nordisk A/S Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 53. Novo Nordisk A/S Recent Development
Table 54. Sanofi S.A. Company Detail
Table 55. Sanofi S.A. Business Overview
Table 56. Sanofi S.A. Metabolic Disorder Therapeutics Product
Table 57. Sanofi S.A. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 58. Sanofi S.A. Recent Development
Table 59. Boehringer Ingelheim GmbH Company Detail
Table 60. Boehringer Ingelheim GmbH Business Overview
Table 61. Boehringer Ingelheim GmbH Metabolic Disorder Therapeutics Product
Table 62. Boehringer Ingelheim GmbH Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 63. Boehringer Ingelheim GmbH Recent Development
Table 64. Eli Lilly and Company Company Detail
Table 65. Eli Lilly and Company Business Overview
Table 66. Eli Lilly and Company Metabolic Disorder Therapeutics Product
Table 67. Eli Lilly and Company Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 68. Eli Lilly and Company Recent Development
Table 69. Merck KgaA Company Detail
Table 70. Merck KgaA Business Overview
Table 71. Merck KgaA Metabolic Disorder Therapeutics Product
Table 72. Merck KgaA Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 73. Merck KgaA Recent Development
Table 74. Amgen, Inc. Company Detail
Table 75. Amgen, Inc. Business Overview
Table 76. Amgen, Inc. Metabolic Disorder Therapeutics Product
Table 77. Amgen, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 78. Amgen, Inc. Recent Development
Table 79. AstraZeneca PLC Company Detail
Table 80. AstraZeneca PLC Business Overview
Table 81. AstraZeneca PLC Metabolic Disorder Therapeutics Product
Table 82. AstraZeneca PLC Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 83. AstraZeneca PLC Recent Development
Table 84. Actelion Pharmaceuticals Ltd. Company Detail
Table 85. Actelion Pharmaceuticals Ltd. Business Overview
Table 86. Actelion Pharmaceuticals Ltd. Metabolic Disorder Therapeutics Product
Table 87. Actelion Pharmaceuticals Ltd. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 88. Actelion Pharmaceuticals Ltd. Recent Development
Table 89. Shire PLC Company Detail
Table 90. Shire PLC Business Overview
Table 91. Shire PLC Metabolic Disorder Therapeutics Product
Table 92. Shire PLC Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 93. Shire PLC Recent Development
Table 94. AbbVie, Inc. Company Detail
Table 95. AbbVie, Inc. Business Overview
Table 96. AbbVie, Inc. Metabolic Disorder Therapeutics Product
Table 97. AbbVie, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 98. AbbVie, Inc. Recent Development
Table 99. Biocon Ltd. Company Detail
Table 100. Biocon Ltd. Business Overview
Table 101. Biocon Ltd. Metabolic Disorder Therapeutics Product
Table 102. Biocon Ltd. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 103. Biocon Ltd. Recent Development
Table 104. BioMarin Pharmaceutical, Inc. Company Detail
Table 105. BioMarin Pharmaceutical, Inc. Business Overview
Table 106. BioMarin Pharmaceutical, Inc. Metabolic Disorder Therapeutics Product
Table 107. BioMarin Pharmaceutical, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 108. BioMarin Pharmaceutical, Inc. Recent Development
Table 109. Bristol-Myers Squibb Company Company Detail
Table 110. Bristol-Myers Squibb Company Business Overview
Table 111. Bristol-Myers Squibb Company Metabolic Disorder Therapeutics Product
Table 112. Bristol-Myers Squibb Company Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 113. Bristol-Myers Squibb Company Recent Development
Table 114. Cipla, Inc. Company Detail
Table 115. Cipla, Inc. Business Overview
Table 116. Cipla, Inc. Metabolic Disorder Therapeutics Product
Table 117. Cipla, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 118. Cipla, Inc. Recent Development
Table 119. CymaBay Therapeutics, Inc. Company Detail
Table 120. CymaBay Therapeutics, Inc. Business Overview
Table 121. CymaBay Therapeutics, Inc. Metabolic Disorder Therapeutics Product
Table 122. CymaBay Therapeutics, Inc. Revenue in Metabolic Disorder Therapeutics Business (2019-2024) & (US$ Million)
Table 123. CymaBay Therapeutics, Inc. Recent Development
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Metabolic Disorder Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Metabolic Disorder Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. Lysosomal Storage Diseases Features
Figure 4. Diabetes Features
Figure 5. Obesity Features
Figure 6. Inherited Metabolic Disorders Features
Figure 7. Hypercholesterolemia Features
Figure 8. Global Metabolic Disorder Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 9. Global Metabolic Disorder Therapeutics Market Share by Application: 2023 VS 2030
Figure 10. Oral Case Studies
Figure 11. Parenteral Case Studies
Figure 12. Others Case Studies
Figure 13. Metabolic Disorder Therapeutics Report Years Considered
Figure 14. Global Metabolic Disorder Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 15. Global Metabolic Disorder Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Metabolic Disorder Therapeutics Market Share by Region: 2023 VS 2030
Figure 17. Global Metabolic Disorder Therapeutics Market Share by Players in 2023
Figure 18. Global Top Metabolic Disorder Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disorder Therapeutics as of 2023)
Figure 19. The Top 10 and 5 Players Market Share by Metabolic Disorder Therapeutics Revenue in 2023
Figure 20. North America Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. North America Metabolic Disorder Therapeutics Market Share by Country (2019-2030)
Figure 22. United States Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Canada Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Metabolic Disorder Therapeutics Market Share by Country (2019-2030)
Figure 26. Germany Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. France Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. U.K. Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Italy Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Russia Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Nordic Countries Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Metabolic Disorder Therapeutics Market Share by Region (2019-2030)
Figure 34. China Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Japan Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. South Korea Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Southeast Asia Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. India Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Australia Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Metabolic Disorder Therapeutics Market Share by Country (2019-2030)
Figure 42. Mexico Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Brazil Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Metabolic Disorder Therapeutics Market Share by Country (2019-2030)
Figure 46. Turkey Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Saudi Arabia Metabolic Disorder Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Novo Nordisk A/S Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)
Figure 49. Sanofi S.A. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)
Figure 50. Boehringer Ingelheim GmbH Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)
Figure 51. Eli Lilly and Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)
Figure 52. Merck KgaA Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)
Figure 53. Amgen, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)
Figure 54. AstraZeneca PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)
Figure 55. Actelion Pharmaceuticals Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)
Figure 56. Shire PLC Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)
Figure 57. AbbVie, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)
Figure 58. Biocon Ltd. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)
Figure 59. BioMarin Pharmaceutical, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)
Figure 60. Bristol-Myers Squibb Company Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)
Figure 61. Cipla, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)
Figure 62. CymaBay Therapeutics, Inc. Revenue Growth Rate in Metabolic Disorder Therapeutics Business (2019-2024)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
